| RAPT THERAPEUTICS |
| USA |
| Gesundheit |
| US75382E2081 / A418SN |
| 0RA0 (Frankfurt) / RAPT (NASDAQ) |
| FRA:0RA0, ETR:0RA0, 0RA0:GR, NASDAQ:RAPT |
| - |
| https://rapt.com/ |
|
Rapt Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunologic diseases. It utilizes deep proprietary exper..
>Volltext.. |
| 1408.28 Mio. EUR |
| 1275.31 Mio. EUR |
| - |
| -95.77 Mio. EUR |
| -92.53 Mio. EUR |
| -9.7 EUR |
| 2.27 Mio. EUR |
| 33.22 Mio. EUR |
| -75.84 Mio. EUR |
| 11.76 |
| - |
| 6.75% |
| - |
| - |
| - |
| - |
| RAPT THERAPEUTICS, RAPT THERAPEUTIC |
| 03.04.26 |
|